Ubs Asset Management Americas Inc Intra Cellular Therapies, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 323,208 shares of ITCI stock, worth $27.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

323,208

Previous 312,104 3.56%

Holding current value

$27.9 Million

Previous $21.4 Million 10.55%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$67.99 - $80.84 $754,960 - $897,647	11,104 Added 3.56%	323,208 $23.6 Million
Q2 2024 Aug 13, 2024	BUY	$64.76 - $79.84 $5.26 Million - $6.48 Million	81,194 Added 35.16%	312,104 $21.4 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $1.07 Million - $1.26 Million	16,629 Added 7.76%	230,910 $16 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $201,524 - $320,082	4,346 Added 2.07%	214,281 $15.3 Million
Q3 2023 Nov 13, 2023	BUY	$52.09 - $64.1 $240,812 - $296,334	4,623 Added 2.25%	209,935 $10.9 Million
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $201,436 - $262,097	4,599 Added 2.29%	205,312 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $655,805 - $810,270	14,881 Added 8.01%	200,713 $10.6 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $2.38 Million - $3.34 Million	-55,669 Reduced 23.05%	185,832 $8.65 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $246,519 - $376,314	-5,733 Reduced 2.32%	241,501 $13.8 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $6.74 Million - $10.8 Million	174,038 Added 237.77%	247,234 $15.1 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $371,360 - $563,581	-10,550 Reduced 12.6%	73,196 $3.83 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $110,428 - $163,374	3,845 Added 4.81%	83,746 $3.12 Million
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $371,904 - $564,838	12,693 Added 18.89%	79,901 $3.26 Million
Q1 2021 May 14, 2021	SELL	$30.8 - $39.51 $13,428 - $17,226	-436 Reduced 0.64%	67,208 $2.28 Million
Q4 2020 Mar 01, 2021	BUY	$23.34 - $32.22 $372,086 - $513,651	15,942 Added 30.83%	67,644 $2.15 Million
Q3 2020 Nov 13, 2020	BUY	$17.61 - $31.86 $90,057 - $162,932	5,114 Added 10.98%	51,702 $1.33 Million
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $645 - $1,198	45 Added 0.1%	46,588 $1.2 Million
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $97,618 - $262,641	7,930 Added 20.54%	46,543 $715,000
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $14,287 - $75,748	-1,968 Reduced 4.85%	38,613 $1.32 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $68,103 - $127,911	9,117 Added 28.98%	40,581 $303,000
Q2 2019 Aug 15, 2019	BUY	$10.65 - $14.29 $12,183 - $16,347	1,144 Added 3.77%	31,464 $0
Q1 2019 May 14, 2019	BUY	$10.9 - $14.09 $170,258 - $220,085	15,620 Added 106.26%	30,320 $0
Q4 2017 Feb 09, 2018	BUY	$14.27 - $16.79 $209,769 - $246,813	14,700	14,700 $0

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.16B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Intra Cellular Therapies, Inc. Transaction History